Palvella Therapeutics, Inc. (PVLA)
NASDAQ: PVLA · Real-Time Price · USD
20.87
+0.36 (1.76%)
Jun 20, 2025, 9:47 AM - Market open

Palvella Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22
Selling, General & Admin
8.975.943.084.16
Research & Development
11.248.158.7913.88
Operating Expenses
20.2114.111.8718.04
Operating Income
-20.21-14.1-11.87-18.04
Interest Expense
-4.73-4.32--10.36
Interest & Investment Income
0.67-6.27-
Other Non Operating Income (Expenses)
0.09-0.121.2-0.17
EBT Excluding Unusual Items
-24.18-18.53-4.41-28.58
Other Unusual Items
1.11.123.1-
Pretax Income
-23.08-17.4318.69-28.58
Income Tax Expense
----1.03
Net Income
-23.08-17.4318.69-27.55
Preferred Dividends & Other Adjustments
-0.19-14.81-
Net Income to Common
-22.89-17.433.88-27.55
Shares Outstanding (Basic)
5226
Shares Outstanding (Diluted)
5226
Shares Change (YoY)
462.52%24.08%-68.63%-
EPS (Basic)
-5.05-7.832.19-4.82
EPS (Diluted)
-5.05-7.832.17-4.82
EBIT
-20.21-14.1-11.87-18.04
Updated Mar 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q